Hepatocellular carcinoma (HCC)βthe most common form of liver cancerβis an aggressive malignancy with few effective treatment options1. Lenvatinib is a small-molecule inhibitor of multiple receptor tyrosine kinases that is used for the treatment of patients with advanced HCC, but this drug has only limited clinical benefit2. Here, using a kinome-centred CRISPRβCas9 genetic screen, we show …
Continue reading #EGFR activation limits the response of #liver cancer to lenvatinib